©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. May 4, 2015; 4(2): 105-115
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.105
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.105
Anticoagulant modulation of inflammation in severe sepsis
Karen S Allen, Eva Sawheny, Gary T Kinasewitz, Section of Pulmonary and Critical Care, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest: All authors have no conflicts of interest.
Correspondence to: Karen S Allen, MD, Assistant Professor of Medicine, Section of Pulmonary and Critical Care, University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd WP1310, Oklahoma City, OK 73104, United States. karen-allen@ouhsc.edu
Telephone: +1-405-2716173
Received: October 16, 2014
Peer-review started: October 16, 2014
First decision: December 17, 2014
Revised: January 13, 2015
Accepted: February 4, 2015
Article in press: February 9, 2015
Published online: May 4, 2015
Processing time: 189 Days and 7.3 Hours
Peer-review started: October 16, 2014
First decision: December 17, 2014
Revised: January 13, 2015
Accepted: February 4, 2015
Article in press: February 9, 2015
Published online: May 4, 2015
Processing time: 189 Days and 7.3 Hours
Core Tip
Core tip: The interaction between the coagulation and inflammatory cascade contributes to the overall pathophysiology of severe sepsis. These processes become unchecked and thus can lead to significant morbidity and mortality. Many anticoagulants have been studied in clinical trials as a means to modulate the inflammatory and coagulation cascade with the aim to improve outcomes for septic patients via modulation of these cascades. This article outlines the pathophysiology and interaction between inflammation and coagulation in severe sepsis and also reviews the anticoagulants previously studied for modulation.